Intervention

BKM120

ClinicalTrials.gov intervention label

Clinical trials27
Recruiting0
Common conditions25
Lead sponsors shown14

Clinical trials

27 shown
Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast CancerNCT02404844 · 2014-12-01
COMPLETED
Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast CancerNCT01953445 · 2014-08-01
WITHDRAWN
Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung CancerNCT02194049 · 2014-07-01
COMPLETED
STAR Cape+BKM120 MBC With Brain MetNCT02000882 · 2014-05-29
COMPLETED
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast CancerNCT02088684 · 2014-05-19
COMPLETED
NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast CancerNCT01816594 · 2013-09-03
COMPLETED
Neoadjuvant BKM120 in High-risk Prostate CancerNCT01695473 · 2013-04-23
TERMINATED
Palliative Thoracic Radiotherapy Plus BKM120NCT02128724 · 2013-04-01
COMPLETED
BKM120+Abiraterone Acetate for Metastatic CRPCNCT01741753 · 2012-11-01
TERMINATED
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORiNCT01633060 · 2012-10-03
TERMINATED
Pharmacodynamic Study of BKM120 in Breast CancerNCT01513356 · 2012-10-01
COMPLETED
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) PatientsNCT01634061 · 2012-09-01
COMPLETED
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase InhibitorNCT01610284 · 2012-08-07
COMPLETED
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K ActivationNCT01572727 · 2012-08-01
COMPLETED
A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid TumorsNCT01626209 · 2012-07-01
COMPLETED
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid TumorsNCT01576666 · 2012-07-01
COMPLETED
BKM120 For Triple Negative Breast CancerNCT01790932 · 2012-06-01
COMPLETED
A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast CancerNCT01629615 · 2012-06-01
COMPLETED
BKM120 in Cancers With PIK3CA Activating MutationsNCT01501604 · 2012-01-01
WITHDRAWN
A Phase I Study of BKM120 and Everolimus in Advanced Solid MalignanciesNCT01470209 · 2012-01-01
COMPLETED
BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast CancerNCT01339442 · 2011-11-14
COMPLETED
BKM120 in Metastatic Castration-resistant Prostate CancerNCT01385293 · 2011-08-01
TERMINATED
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung CancerNCT01297491 · 2011-05-01
COMPLETED
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast CancerNCT01248494 · 2010-11-01
COMPLETED
Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast CancerNCT01132664 · 2010-05-01
TERMINATED
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor PatientsNCT01155453 · 2010-04-01
COMPLETED
Safety of BKM120 Monotherapy in Advanced Solid Tumor PatientsNCT01068483 · 2008-11-01
COMPLETED

Common conditions

Breast Cancer10Metastatic Breast Cancer5Lung Cancer2Prostate Cancer2Solid Tumors2Advanced and Selected Solid Tumors1Advanced Breast Cancer, Advanced Carcinomas With Squamous Cell Histology1Advanced Pancreatic Adenocarcinoma1Advanced Solid Tumors1Brain Metastases1Breast Neoplasms1Carcinoma, Non-Small-Cell Lung1Castration-resistant Prostate Cancer1Cholangiocarcinoma1Colon Cancer1Colorectal Cancer1Dose Escalation1Endometrium Cancer1Estrogen Receptor-positive Breast Cancer1Extensive Stage Small Cell Lung Cancer1Gastric Cancer1Gastroesophageal Junction Cancer1HER2-positive Newly Diagnosed, Primary Breast Cancer1HER2+ Breast Cancer1High Risk Prostate Cancer1

Trial status mix

COMPLETED20
TERMINATED5
WITHDRAWN2

Phase mix

PHASE113
PHASE212
PHASE33
EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.